carsgen therapeutics hldgs ltd - CRTHF

CRTHF

Close Chg Chg %
0.75 0.01 1.81%

Closed Market

0.76

+0.01 (1.81%)

Volume: 2.00K

Last Updated:

Jun 14, 2024, 9:30 AM EDT

Company Overview: carsgen therapeutics hldgs ltd - CRTHF

CRTHF Key Data

Open

$0.76

Day Range

0.76 - 0.76

52 Week Range

0.75 - 1.67

Market Cap

$349.25M

Shares Outstanding

572.55M

Public Float

351.80M

Beta

0.45

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

N/A

 

CRTHF Performance

No Data Available

CRTHF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About carsgen therapeutics hldgs ltd - CRTHF

CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The firm focuses on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company was founded by Zong Hai Li and Hua Mao Wang on February 9, 2018, and is headquartered in Shanghai, China.

CRTHF At a Glance

CARsgen Therapeutics Holdings Ltd.
CMC Preparation Center
Shanghai, Shanghai 200231
Phone N/A Revenue 0.00
Industry Pharmaceuticals: Major Net Income -105,545,657.23
Sector Health Technology Employees 516
Fiscal Year-end 12 / 2024
View SEC Filings

CRTHF Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 1.886
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.149
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.056

CRTHF Efficiency

Revenue/Employee N/A
Income Per Employee -204,545.847
Receivables Turnover N/A
Total Asset Turnover N/A

CRTHF Liquidity

Current Ratio 9.546
Quick Ratio 9.493
Cash Ratio 9.427

CRTHF Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -29.494
Return on Equity -34.616
Return on Total Capital -39.671
Return on Invested Capital -33.308

CRTHF Capital Structure

Total Debt to Total Equity 4.73
Total Debt to Total Capital 4.516
Total Debt to Total Assets 3.775
Long-Term Debt to Equity 3.911
Long-Term Debt to Total Capital 3.735
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Carsgen Therapeutics Hldgs Ltd - CRTHF

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - - 4.00M
-
Sales Growth
- - - -100.00%
-
Cost of Goods Sold (COGS) incl D&A
- 5.81M 12.11M 12.34M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.81M 8.13M 12.11M 12.34M
Depreciation
4.96M 7.20M 11.08M 11.29M
Amortization of Intangibles
848.71K 930.33K 1.03M 1.04M
COGS Growth
- - +105.19% +1.87%
-
Gross Income
- (5.81M) (12.11M) (12.34M)
Gross Income Growth
- - -105.19% -1.87%
-
Gross Profit Margin
- - - -
-
2020 2021 2022 2023 5-year trend
SG&A Expense
46.15M 89.17M 109.09M 99.64M
Research & Development
35.25M 70.09M 90.16M 82.91M
Other SG&A
10.90M 19.08M 18.93M 16.73M
SGA Growth
+43.23% +93.22% +22.33% -8.66%
Other Operating Expense
- - - -
-
Unusual Expense
- - 104.94M 644.34M
-
EBIT after Unusual Expense
(156.90M) (737.64M) (121.20M) (111.98M)
Non Operating Income/Expense
4.69M 4.87M (8.81M) 7.15M
Non-Operating Interest Income
110.54K 1.49M 4.09M 10.27M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.95M 1.69M 2.30M 658.29K
Interest Expense Growth
+1,421.41% -13.71% +36.77% -71.44%
Gross Interest Expense
1.95M 1.69M 2.30M 658.29K
Interest Capitalized
- - - -
-
Pretax Income
(154.16M) (734.46M) (132.31M) (105.49M)
Pretax Income Growth
-301.77% -376.43% +81.99% +20.27%
Pretax Margin
- - - -18,350.36%
-
Income Tax
- 1.19M 192.32K 57.45K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- 1.19M 192.32K 57.45K
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(154.16M) (735.64M) (132.50M) (105.55M)
Minority Interest Expense
- - - -
-
Net Income
(154.16M) (735.64M) (132.50M) (105.55M)
Net Income Growth
-301.77% -377.19% +81.99% +20.35%
Net Margin Growth
- - - -18,379.98%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(154.16M) (735.64M) (132.50M) (105.55M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(154.16M) (735.64M) (132.50M) (105.55M)
EPS (Basic)
-0.2651 -1.2962 -0.2402 -0.1898
EPS (Basic) Growth
-301.67% -388.95% +81.47% +20.98%
Basic Shares Outstanding
581.56M 567.54M 551.63M 556.13M
EPS (Diluted)
-0.2651 -1.2962 -0.2402 -0.1898
EPS (Diluted) Growth
-301.67% -388.95% +81.47% +20.98%
Diluted Shares Outstanding
581.56M 567.54M 551.63M 556.13M
EBITDA
(46.15M) (85.17M) (109.09M) (99.64M)
EBITDA Growth
-43.23% -84.55% -28.08% +8.66%
EBITDA Margin
- - - -2,127.97%
-

Carsgen Therapeutics Hldgs Ltd in the News